Mycophenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in immunosuppressive protocols targeting organ transplantation and selected autoimmune diseases.

• Solid‑organ transplant rejection prevention: reduces incidence of acute rejection episodes in kidney, heart and liver recipients.
• Maintenance immunosuppression in transplant recipients: supports long‑term graft survival as part of combination therapy.
• Autoimmune disease management (off‑label): employed in lupus nephritis and certain vasculitides to control disease activity.

• Mycophenolate Mofetil is selectively converted to mycophenolic acid, which inhibits inosine monophosphate dehydrogenase (IMPDH). This enzyme catalyzes the de novo synthesis of guanosine nucleotides. By blocking IMPDH, the drug depletes guanosine pools, impairing DNA synthesis and proliferation of activated T and B lymphocytes, while sparing resting cells, thereby providing targeted immunosuppression. The selective effect on lymphocytes underlies its efficacy in preventing graft rejection and controlling autoimmune inflammation.

Mycophenolate Mofetil may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, may lead to dehydration.
• Abdominal pain: cramping or discomfort in the stomach area.
• Headache: transient mild to moderate pain.
• Infections: increased susceptibility to bacterial, viral or fungal infections.
• Leukopenia: reduction in white blood cell count.

Serious or Rare Side Effects

• Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Malignancy: increased risk of lymphoproliferative disorders and skin cancers.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease.
• Bone marrow suppression: pancytopenia leading to anemia, thrombocytopenia.
• Hepatic toxicity: elevated liver enzymes or hepatitis.

When prescribing Mycophenolate Mofetil, clinicians should observe several safety measures to minimize risks.

• Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia.
• Assess renal function: adjust therapy based on creatinine clearance and monitor for nephrotoxicity.
• Avoid live vaccines: patients should not receive live attenuated vaccines while on therapy.
• Pregnancy risk: drug is classified as Category D; discontinue if pregnancy is confirmed unless benefits outweigh risks.
• Drug interactions: review concomitant medications for potential additive immunosuppression.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil interacts with several agents that can alter its efficacy or safety profile.

Major Interactions (Avoid)

• Azathioprine: combined use markedly increases risk of bone marrow suppression.
• Cyclosporine or tacrolimus: may raise mycophenolate exposure and heighten toxicity.
• Cholestyramine or other bile‑acid sequestrants: reduce oral absorption of mycophenolate.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• ACE inhibitors or ARBs: combined use can affect renal function, necessitating periodic assessment.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal irritation and renal impairment.